Lowering LDL cholesterol is good, but how and in whom?
Two reports now published in the Journal describe the results of long-term studies of treatment with monoclonal antibodies to PCSK9 to lower LDL cholesterol levels. One trial, entitled Long-Term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM), was a double-blind, randomized, controlled trial of alirocumab (150 mg administered subcutaneously every 2 weeks) versus placebo for 78 weeks in 2341 patients at high risk for cardiovascular events who were already receiving the maximum tolerated doses of statins..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:372 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 372(2015), 16, Seite 1564 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stone, Neil J [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1056/NEJMe1502192 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1968371761 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1968371761 | ||
| 003 | DE-627 | ||
| 005 | 20220223153649.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMe1502192 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1968371761 | ||
| 035 | |a (DE-599)GBVOLC1968371761 | ||
| 035 | |a (PRQ)c1943-8cfb1a259c3c253ccf2409d27080f59f429fbb43343b3a57068008bf46e39f060 | ||
| 035 | |a (KEY)0171808820150000372001601564loweringldlcholesterolisgoodbuthowandinwhom | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Stone, Neil J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lowering LDL cholesterol is good, but how and in whom? |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Two reports now published in the Journal describe the results of long-term studies of treatment with monoclonal antibodies to PCSK9 to lower LDL cholesterol levels. One trial, entitled Long-Term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY LONG TERM), was a double-blind, randomized, controlled trial of alirocumab (150 mg administered subcutaneously every 2 weeks) versus placebo for 78 weeks in 2341 patients at high risk for cardiovascular events who were already receiving the maximum tolerated doses of statins. | ||
| 650 | 4 | |a Hypercholesterolemia - drug therapy | |
| 650 | 4 | |a Anticholesteremic Agents - therapeutic use | |
| 650 | 4 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | |
| 650 | 4 | |a Cholesterol, LDL - blood | |
| 650 | 4 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | |
| 650 | 4 | |a Antibodies, Monoclonal - therapeutic use | |
| 650 | 4 | |a Cardiovascular Diseases - prevention & control | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Analysis | |
| 650 | 4 | |a Care and treatment | |
| 650 | 4 | |a Dosage and administration | |
| 650 | 4 | |a Cholesterol, LDL | |
| 650 | 4 | |a Practice guidelines (Medicine) | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Usage | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Statins | |
| 650 | 4 | |a Low density lipoprotein | |
| 650 | 4 | |a Heart attacks | |
| 650 | 4 | |a Cardiovascular disease | |
| 700 | 1 | |a Lloyd-Jones, Donald M |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 372(2015), 16, Seite 1564 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:372 |g year:2015 |g number:16 |g pages:1564 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1056/NEJMe1502192 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25773740 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1673852041 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_287 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2012 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 372 |j 2015 |e 16 |h 1564 | ||